LIVN vs. TMDX, CNMD, ITGR, INMD, HAE, SLNO, BLFS, AXGN, OM, and MASI
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include TransMedics Group (TMDX), CONMED (CNMD), Integer (ITGR), InMode (INMD), Haemonetics (HAE), Soleno Therapeutics (SLNO), BioLife Solutions (BLFS), AxoGen (AXGN), Outset Medical (OM), and Masimo (MASI). These companies are all part of the "medical" sector.
LivaNova (NASDAQ:LIVN) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
97.6% of LivaNova shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 0.2% of LivaNova shares are held by insiders. Comparatively, 6.7% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
LivaNova has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
LivaNova currently has a consensus target price of $64.40, suggesting a potential upside of 15.97%. TransMedics Group has a consensus target price of $102.00, suggesting a potential upside of 10.77%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than TransMedics Group.
In the previous week, LivaNova and LivaNova both had 5 articles in the media. TransMedics Group's average media sentiment score of 0.82 beat LivaNova's score of 0.15 indicating that TransMedics Group is being referred to more favorably in the news media.
LivaNova has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
LivaNova has a net margin of 1.53% compared to TransMedics Group's net margin of -10.36%. LivaNova's return on equity of 12.23% beat TransMedics Group's return on equity.
LivaNova received 296 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 68.80% of users gave LivaNova an outperform vote while only 53.29% of users gave TransMedics Group an outperform vote.
Summary
LivaNova beats TransMedics Group on 10 of the 17 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
